Inactive Instrument

Highlights Progenics Pharmaceuticals, Inc.

Equities

US7431871067

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Perspective Therapeutics, Inc. completed the acquisition of Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey from Progenics Pharmaceuticals, Inc.	Feb. 29	CI
Perspective Therapeutics, Inc. entered into an asset purchase agreement to acquire Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey from Progenics Pharmaceuticals, Inc. for $8 million.	Jan. 08	CI
International Isotopes Inc. Terminates Manufacturing and Supply Agreement with Progenics Pharmaceuticals, Inc	20-12-28	CI
Progenics Pharmaceuticals : Lantheus Completes Merger with Progenics	20-06-22	BU
Lantheus Holdings, Inc. completed the acquisition of Progenics Pharmaceuticals, Inc. from Velan Capital, L.P., Virinder Nohria, LTE Partners, LLC, Terence Cooke, Gérard Ber and others.	20-06-18	CI
Progenics Stockholders Approve Merger with Lantheus	20-06-16	GL
Progenics Pharmaceuticals, Inc. Announces Results from the Phase 3 Condor Trial of Pyl™	20-05-18	CI
Progenics Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	20-05-07	CI
Lantheus : Velan Capital Agrees to Support Merger of Lantheus and Progenics	20-04-15	AQ
Progenics Pharmaceuticals : ADDING MULTIMEDIA Velan Capital Agrees to Support Merger of Lantheus and Progenics	20-04-14	BU
Velan Capital Agrees to Support Merger of Lantheus and Progenics	20-04-14	CI
Progenics Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2019	20-03-13	CI
Progenics Pharmaceuticals Announces Phase 3 CONDOR Trial of PyL™ in Prostate Cancer	19-12-23	CI
Progenics Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-11-07	CI
Progenics Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2019	19-11-07	CI
Lantheus Holdings, Inc. entered into a definitive agreement to acquire Progenics Pharmaceuticals, Inc. from Velan Capital, L.P., Virinder Nohria, LTE Partners, LLC, Terence Cooke, Gérard Ber and others for approximately $440 million.	19-10-01	CI
Progenics Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	19-08-09	CI
CMS Grants New Technology Add-On Payment for Inpatient Use of Azedra® (Iobenguane I 131) from Progenics Pharmaceuticals	19-08-06	CI
Progenics Pharmaceuticals Completes Enrollment in Pivotal Phase 3 CONDOR Study of PyL for the Detection of Prostate Cancer	19-08-05	CI
Progenics Pharmaceuticals, Inc. Announces Collaboration with VA Greater Los Angeles Healthcare System on the AI Research Program for Medical Image Analysis	19-07-25	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Progenics Pharmaceuticals, Inc.

Equities

US7431871067

Highlights

Filters